Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus
Gore, T.C.; Lakshmanan, N.; Duncan, K.L.; Coyne, M.J.; Lum, M.A.; Sterner, F.J.
Veterinary Therapeutics Research in Applied Veterinary Medicine 6(1): 5-14
2005
ISSN/ISBN: 1528-3593 PMID: 15906266 Document Number: 321
A challenge-of-immunity study was conducted to demonstrate immunity in dogs 3 years after their second vaccination with a new multivalent, modified-live vaccine containing canine adenovirus type-2, canine parvovirus (CPV), and canine distemper virus (CDV). Twenty-three seronegative pups were vaccinated at 7 and 11 weeks of age. Eighteen seronegative pups, randomized into groups of six dogs, served as challenge controls. Dogs were kept in strict isolation for 3 years following the last vaccination and then challenged sequentially with virulent canine adenovirus type-1 (CAV-1), CPV, and CDV. For each viral challenge, a separate group of six control dogs was also challenge. Clinical signs of CAV-1, CPV, and CDV infections were prevented in 100% of vaccinated dogs, demonstrating that the multivalent, modified-live test vaccine provided protection against virulent CAV-1, CPV, and CDV challenge in dogs 7 weeks of age or older for a minimum of 3 years following second vaccination.
Document emailed within 1 workday
